Illumina (ILMN) has lost about 14.6% over five days despite a third-quarter report that beat estimates and raised full-year guidance. It bounced 5.0% to $237.95 on November 3, 2026, on light volume. The weekly uptrend is intact, but the stock sits below its 50-day average and has lagged both the S&P 500 and healthcare. The balance of evidence for the next two to six weeks is even, with low conviction.
Why it matters
The quarter itself was good. Revenue was $1.13 billion, up 4% from a year earlier, and net income rose 47% to $220.0 million, according to the 10-Q filing. On the earnings call, management said non-GAAP EPS of $1.44 beat guidance on every metric. It also raised full-year revenue guidance to $4.64–$4.66 billion and EPS guidance to $5.40–$5.45.
The stock fell anyway, because it had run too far. Investor's Business Daily framed the drop as tariff confusion and a weak backdrop for AI-linked technology names eating into a 157% run-up. Investing.com pointed to China, where revenue slipped 0.1%, and to a management warning of a mid-to-high single-digit decline. The summary is cut off before saying where. Shares were up 82% for the year and 76% over six months, so a beat that merely met lofty expectations was enough to trigger selling. The stock peaked at $293.69 on October 5 and now sits 19% below that.
Almost all of the five-day damage belongs to the stock itself. ILMN fell 14.6%, while the S&P 500 (SPY) lost 2.1% and the healthcare sector ETF (XLV) gained 2.8%. That leaves the stock about 17 points behind its sector. XLV had a strong October, up 9.53% as money rotated out of technology, Seeking Alpha reported, and ILMN did not share in it. Today's 5.0% bounce came on volume 38% below the 20-day average. A Singapore genome-sequencing award for about 450,000 people landed the same day, but a light-volume rebound is not strong evidence that buyers have returned.
The argument is about durability. The bull case, laid out by Seeking Alpha with a $293.77 figure, rests on NovaSeq X, premium pricing against rivals such as MGI Tech, and a possible lift from the BIOSECURE Act. The cautious side points to China and to a fund exit: Brown Advisory sold its Illumina position in the third quarter. On valuation, 20 analysts rate the stock a hold with a mean price target of $261.6, about 9% above the price. Targets range from $165 to $365, which shows how little agreement there is on what the stock is worth.
What the evidence says
The long-term thesis is intact but in a correction phase. Price is above its 40-week average and far above the 200-day average at $176.99, and it is 108% above its 52-week low of $114.44. Against the S&P 500, the stock is still 31% ahead over 200 days. The damage is recent: the stock is below its 10-week average and under the 50-day average at $249.74, with RSI at 37.8.
For the next two to six weeks the evidence is even, and conviction is low, at 0 of 4 points. The drop is a pullback against a rising weekly trend that is not yet stretched. That would normally favor the trend, but the stock trails the S&P 500 by 3.0% over 50 days and XLV by 10.8%, so relative strength is going the wrong way. Neither side has enough evidence to lean on.
The strongest case against an even reading is the fundamental one. Guidance was raised, earnings grew 47%, and the stock is 19% off its high with a price target above the market. That could turn into a sharp recovery. It does not tip the balance because price has not confirmed it: the stock is below the 50-day average, volume on the bounce is thin, and the sector rallied without it. That gap is why conviction is not higher.
Levels that matter
The structure holds above $225, a round number and the first support under the price. A break below it would be the first crack, with $200 and the $178.05 swing zone next. The trend itself ends below $176.99, the 200-day average, which is also close to that swing zone. A weekly close there would mean the whole advance is being unwound.
The breakout level is a daily close above $249.74, the 50-day average, on volume above its 20-day average. From there the nearest targets are $275 and the 52-week high of $293.69. Measured to $293.69 against a stop at $220.60 (a quarter of ATR under $225), the math gives 1.5 to 1. That does not reach the 3 to 1 that makes a breakout worth the risk. It would take a target well beyond the high, such as the $365 top analyst target, or a much closer stop after a pullback toward $225 and a later reclaim.
What would change the picture
A weekly close below $176.99, the 200-day average, would change the picture. The one non-price fact that could cause it is a cut to the raised guidance, or evidence that the China weakness is spreading beyond the 0.1% decline in the quarter. Either would undermine the case that this was a valuation reset rather than a change in the business.
What to watch
- Earnings: the third-quarter report is out, and the next date is not yet in the data. The number to track is China revenue, which fell 0.1%, along with the $4.64–$4.66 billion full-year revenue range.
- Sector: XLV's October rally and the rotation out of technology matter before ILMN's own news. If that rotation reverses, healthcare support fades, and ILMN has not been taking part in it anyway.
- Valuation: at $237.95 the stock is about 9% below the $261.6 mean target, inside a $165–$365 range, with a consensus of hold.